Compound cough-relieving and anti-asthma decoction

Abstract

The invention relates to the field of formula of traditional Chinese medicines, in particular to compound cough-relieving and anti-asthma decoction. The compound cough-relieving and anti-asthma decoction is prepared by soaking raw materials into water, decocting and removing dregs to obtain the filtrate, wherein the raw materials comprises the following components as per percentage by weight: 5 to 11 percent of tangerine peel, 8 to 10 percent of pinellia ternate, 5 to 11 percent of houttuynia cordata, 5 to 6 percent of radix stemonae, 8 to 14 percent of sandra chinensis, 5 to 11 percent of poria cocos, 6 to 11 percent of radish seed, 6 to 8 percent of platycodon grandiflorum, 6 to 7 percent of starwort root, 6 to 8 percent of scorched hawthorn fruit, 5 to 6 percent of semen lepidii, 8 to 9 percent of whiteflower hogfennel root, 8 to 9 percent of figwort root and 6 to 8 percent of earthworm. The compound cough-relieving and anti-asthma decoction has low cost, no obvious toxic or side effects and low recurrence rate and can effectively treat cough and asthma.

Description

technical field [0001] The invention relates to a Chinese patent medicine preparation, in particular to a compound decoction for relieving cough and asthma. Background technique [0002] As we all know, the incidence of cough variant asthma has gradually increased in recent years, and its pathogenesis has not been fully understood in western medicine research. Chronic inflammation, causing airway hyperresponsiveness, leading to reversible airway obstruction, is also related to the interaction of allergies, genetics, and neuroimmune factors. [0003] Due to the unclear pathogenesis, there is no specific treatment method and method in western medicine at present. Commonly used symptomatic treatment drugs include: glucocorticoids such as budesonide mixed solution for inhalation, bronchodilator β 2 Receptor agonists (salbutamol aerosol), theophylline drugs (aminophylline), anticholinergic drugs (atropine), leukotriene antagonists (montelukast sodium chewable tablets), antialler...

AI Technical Summary

Problems solved by technology

[0003] Due to the unclear pathogenesis, there is no specific treatment method and method in western medicine at present. Commonly used symptomatic treatment drugs include: glucocorticoids such as budesonide mixed solution for inhalation, bronchodilator β 2 Receptor agonists (salbutamol aerosol), theophylline drugs (aminophylline), anticholinergic drugs (atropine), leukotriene antagonists (montelukast sodium chewable tablets), antiallergic and stabilized drugs Cellular drugs (loratadine, cromolyn sodium, ketotifen), etc.

Single or combined medication is often used, there is no uniform medication standard, and the clinical curative effect is uncertain

Among them, albuterol aerosol and budesonide suspension for inhalation need oxygen-driven atomized inhalation, which is inconvenient to use, and some children have adverse reactions such as throat discomfort and moaning hoarseness; some children who take aminophylline and salbutamol tablets can Adverse reactions such as palpitations and tachycardia occur; Montelukast sodium chewable tablets are imported drugs, which are expensive and have uncertain curative effects; long-term use of antiallergic drugs may cause adverse reactions such as drowsiness, fatigue, nausea, dry mouth, and liver function damage , which greatly limits the clinical use of drugs, affects the recovery of the disease, and is prone to relapse after drug withdrawal, which brings serious physical and mental harm to children and parents.

Images